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Abstract
Purpose—Diabetes is a suspected risk factor for pancreatic cancer, but questions remain about
whether it is a risk factor or a result of the disease. This study prospectively examined the
association between diabetes and the risk of pancreatic adenocarcinoma in pooled data from the
NCI pancreatic cancer cohort consortium (PanScan).
Methods—The pooled data included 1,621 pancreatic adenocarcinoma cases and 1,719 matched
controls from twelve cohorts using a nested case–control study design. Subjects who were
diagnosed with diabetes near the time (<2 years) of pancreatic cancer diagnosis were excluded
from all analyses. All analyses were adjusted for age, race, gender, study, alcohol use, smoking,
BMI, and family history of pancreatic cancer.
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Results—Self-reported diabetes was associated with a forty percent increased risk of pancreatic
cancer (OR = 1.40, 95 % CI: 1.07, 1.84). The association differed by duration of diabetes; risk was
highest for those with a duration of 2–8 years (OR = 1.79, 95 % CI: 1.25, 2.55); there was no
association for those with 9+ years of diabetes (OR = 1.02, 95 % CI: 0.68, 1.52).
Conclusions—These findings provide support for a relationship between diabetes and
pancreatic cancer risk. The absence of association in those with the longest duration of diabetes
may reflect hypoinsulinemia and warrants further investigation.
Keywords
Diabetes; Risk factor; Cohort consortium; Pancreatic cancer
Introduction
Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the United States
[1] and annually accounts for more than 227,000 deaths worldwide [2]. It is a highly fatal
disease with a five-year survival rate of less than 5 % [1]. Several risk factors have been
identified including age, smoking, race, sex, diabetes, alcohol intake, ABO blood group,
body mass index (BMI), and family history of pancreatic cancer [3–9]. Pancreatic cancer
risk is higher in Blacks than Whites, men than women, obese than normal weight, and
diabetics compared to non-diabetics [3]. Smoking is the most studied and well-characterized
risk factor; other possible risk factors are less established [3, 4, 10].
Type 2 diabetes, generally discovered during adulthood, is usually marked by an initial
period of relative hyperinsulinemia, in which the mass of the β-cells of the pancreatic islets
of Langerhans is reduced but insulin secretion increased as partial compensation for
increased insulin resistance due to overweight and lack of physical activity, followed later
by a period of relative hypoinsulinemia, reflecting further reduction of the mass of the β-
cells [11]. Hyperglycemia is associated with altered glucose metabolism, chronic
inflammation, oxidative stress, and the activation of insulin signaling cascades that may
increase the risk of pancreatic cancer [12]. Diabetes can also be an early manifestation of
pancreatic cancer, so it is important to determine whether diabetes is an independent risk
factor for pancreatic cancer or instead a consequence of the disease. Pancreatic cancer
progresses without significant early symptoms and is generally diagnosed at late stages. The
development of diabetes within a few years of a pancreatic cancer diagnosis is more likely to
suggest an effect of the tumor, whereas diabetes of longer duration is more likely to
contribute to the development of cancer [13].
Two meta-analyses concluded that diabetes is associated with an increased risk of pancreatic
cancer [14, 15]; however, many of the studies included in these analyses were limited by
low numbers of pancreatic cancer cases, were likely to involve secondary effects of
pancreatic cancer including the induction of diabetes, and had limited numbers of
prospective studies with an evaluation of the long-term effects of diabetes. In addition, these
studies generally did not evaluate the effect of diabetes duration. Thus, additional
investigations with adequate numbers of cases in prospective studies are needed to discern
this complicated relationship, especially in light of the increasing prevalence of diabetes in
many Western countries.
This report examines the association between type 2 diabetes and subsequent pancreatic
adenocarcinoma risk by pooling data from 12 cohort studies in the NCI Pancreatic Cancer
Cohort Consortium (PanScan) using a nested case–control study design. These cohorts have
long-term follow-up and include 1,621 pancreatic adenocarcinoma cases, making this one of
the largest prospective analyses to date of type 2 diabetes and pancreatic cancer.
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PanScan is an initiative that was funded jointly by the National Cancer Institute’s Division
of Cancer Control and Population Sciences and the Division of Cancer Epidemiology and
Genetics in 2006. PanScan includes investigators from 12 prospective epidemiologic cohorts
and one case–control study, the Mayo Clinic Study. It was created to investigate
environmental, lifestyle, and genetic causes of pancreatic cancer. Studies in the pooled
analysis included: The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Trial (ATBC)
[16], CLUE II [17], Cancer Prevention Study II (CPS II) [18], European Prospective
Investigation into Cancer and Nutrition (EPIC) [19], the Health Professionals Follow-up
Study (HPFS) [20], the Mayo Clinic study (MAYO) [21], the New York University
Women’s Health Study (NYUWHS) [22], the Nurses’ Health Study (NHS) [20], the
Physicians’ Health Study (PHS I) [20], the Prostate, Lung, Colorectal, Ovarian Cancer
Screening Trial (PLCO) [23], Shanghai Men’s and Women’s Health Studies (SMWHS) [24,
25], the Women’s Health Initiative (WHI) [26], and the Women’s Health Study (WHS) [27].
Characteristics of these studies have been summarized previously including the years of
recruitment, age range of participants, racial composition, years of follow-up, and matching
criteria [16–27]. The Mayo study was excluded from these analyses due to its case–control
study design. A total of 120 cases and 79 controls had missing data on diabetes and thus
were excluded from analysis. We have also excluded participants diagnosed with diabetes
less than 2 years before pancreatic cancer diagnosis or selection as a control (n = 36) and
also any participants diagnosed with diabetes after cancer/selection (n = 4) in our analyses.
A total of 1,621 cases and 1,719 controls were included in the current analysis.
Case ascertainment and data collection
Cases included all incident primary pancreatic adenocarcinoma (ICD-O-3 codes C25.0–
C25.3, C25.7–C25.9). Endocrine pancreatic tumors (ICD-O-3 code C25.4, histology types
8,150, 8,151, 8,153, 8,155, 8,240, and 8,246) were excluded because the etiology of these
cancers is thought to be different from that of exocrine tumors, which account for the vast
majority of pancreatic tumors. Case ascertainment varied between studies but included
linking participants to cancer registries and national death indices, and using self and next of
kin reports. Most cases were histologically confirmed (ATBC, CLUE II, EPIC, NYUWHS,
SMWHS, WHI) or confirmed through cancer registries (ATBC, CPS II, EPIC, SMWHS),
death certificates (CPS II, EPIC), or review of medical records by medical personnel
(ATBC, CPS II, EPIC, NHS, PHS I, PLCO, SMWHS).
Controls were incidence density-sampled with a 1-to-1 control-to-case ratio and were alive
and cancer-free on the date of diagnosis of the matched case. At a minimum, controls were
matched to cases by calendar year of birth (±5 years), gender, race and ethnicity. Some
cohorts employed more stringent matching on age such as age at baseline or age at blood
draw (±5 years), and additionally, on other relevant factors such as smoking, date/time of
day of blood draw, fasting blood draw (for comparisons of blood levels of analytes of
interest), and length of follow-up. Detailed descriptions of data collection methods have
been published previously by the individual studies [16–27]. Baseline information on BMI,
waist circumference, waist-to-hip ratio, history of cigarette smoking, gender, age, race,
family history of pancreatic cancer in a first-degree relative, alcohol consumption,
pancreatitis, and history of diabetes was requested from the cohorts that collected this
information. Data on diabetes, demographics, and possible confounders were collected
through self-administered written questionnaires or in-person interviews from baseline and/
or follow-up questionnaires, with the most recent data available used in analysis. Self-
reported diabetes status was ascertained based on a physician’s diagnosis of diabetes and/or
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treatment for diabetes with the use of insulin or oral hypoglycemic drugs. The duration of
diabetes was assessed by the reported age at diagnosis, when available, and the reported
follow-up period. When the age of diagnosis was not available, it was estimated from the
date of the follow-up examination that first reported the presence of diabetes. Three cohorts
(ATBC, PLCO, and WHI) did not query age at diabetes diagnosis; these data were missing
for 22 % of participants in the remaining cohorts. Individual datasets were checked for
consistency with previously published results. The Special Studies Institutional Review
Board (SSIRB) of the National Cancer Institute approved the pooled PanScan study. Each
study also was approved by its local IRB.
Statistical analysis
Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for pancreatic cancer risk were
calculated using unconditional logistic regression. Several multivariate models were used to
assess the effects of potential confounders. Unless otherwise noted, models were adjusted
for age (<=50, 51–60, 61–70, 71–80, and 81+ years), gender, race (European, African,
Asian, other, unknown), study, continuous BMI, alcohol use (never, ever current status
unknown, former drinker, light current drinker, heavy current drinker, unknown), smoking
(never, former, current, unknown), and family history of pancreatic cancer. Indicator
variables were used in all analysis for variables with missing responses. No adjustment was
made for pancreatitis because few cohorts had this information. Several approaches,
including visual representation and splines, were used to evaluate the duration of diabetes
when modeling the effect of diabetes on pancreatic cancer risk but did not change results
appreciably. We used cut points of 2–8 years and nine or more years based on the numbers
of responses to ensure adequate cell size for analysis.
We modeled multiplicative interaction terms between diabetes and gender, age, cigarette
smoking status (never, former, current), and continuous BMI and compared p values for the
likelihood ratio tests (<0.05) for the models with and without interaction terms. We also
evaluated heterogeneity across studies by fitting models with and without multiplicative
interaction terms between diabetes and study and calculating a p value for heterogeneity
using the likelihood ratio statistic. All analyses were conducted using SAS version 9.1.3
(SAS Institute Inc, Cary, North Carolina).
Results
Table 1 describes each study in the PanScan study included in these analyses, including the
study location, numbers of participants, age range, method to assess diabetes status, and the
prevalence of diabetes among cases and controls, while Table 2 presents the baseline
characteristics of the participants included. There were approximately equal numbers by age,
gender, and race among cases and controls. There were small numbers of Asians and
Africans, and most of the participants were between the ages of 60 and 80. Cases were more
likely to identify as current smokers than controls (28 vs. 22 %) and were more likely to be
overweight or obese. Cases were more likely to report being diagnosed with diabetes than
controls (10 vs. 7 %). A history of pancreatitis and/or family history of pancreatic cancer
were slightly more common among cases as compared to controls. However, many cohorts
did not collect this information and approximately one-half of the participants lacked these
data. The mean age at pancreatic adenocarcinoma diagnosis was 68.9 years (SD 8.5),
whereas the mean age at diabetes diagnosis was 58.5 years (SD 12.4).
Diabetes was associated with an increased risk of pancreatic cancer (Odds ratio (OR) = 1.37,
95 % CI: 1.06, 1.77); adjustment for age, gender, study, and race had a minor effect on the
odds ratio (OR = 1.49, 95 % CI: 1.14, 1.94), as did adjustment for the full model including
age, race, gender, study, alcohol use, smoking, BMI, and family history of pancreatic cancer
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(OR = 1.40, 95 % CI: 1.07, 1.84). Because a consequence of pancreatic cancer can be the
development of diabetes, all analyses excluded pancreatic cancer cases with diabetes
diagnosed within 2 years of the pancreatic cancer diagnosis, as well as controls diagnosed
with diabetes within 2 years of the diagnosis date of the matched case. When those cases
diagnosed/controls enrolling within 2 years of a diabetes diagnosis were included, the odds
ratio was modestly higher (OR = 1.50, 95 % CI: 1.18, 1.91).
We also examined whether the duration of diabetes was associated with the risk of
pancreatic adenocarcinoma (Table 3). Due to the limited number of cases for some time
periods, several time periods were grouped together to ensure adequate numbers of cases for
analysis. The optimal groupings were cases with a duration of 2–8 years and 9+ years of
duration. Changing the periods of duration within the grouping yielded similar results (Table
4). The risk of pancreatic adenocarcinoma was elevated when the duration of diabetes
ranged from 2–8 years (OR = 1.79, 95 % CI: 1.25, 2.55). Interestingly, the risk of pancreatic
adenocarcinoma decreased with a duration of diabetes of 9+ years (OR = 1.02, 95 % CI:
0.68, 1.52) as compared to a duration of diabetes from 2–8 years. Similar results were found
for men (OR = 1.79, 95 % CI: 1.00, 3.21) and women (OR = 1.81, 95 % CI: 1.15, 2.87) for
those with a duration of diabetes for 2–8 years. In a fully adjusted model, we adjusted for the
potential confounders of age, gender, race, study, BMI, alcohol use, smoking, and family
history of pancreatic cancer. Examination of possible effect modification with BMI, age, and
smoking did not reveal any statistically significant interactions. In addition, we tested for
heterogeneity among the studies included in these analyses using Cochran’s Q test and
found no evidence of heterogeneity (p = 0.317 for 2–8 years and p = 0.923 for 9+ years
duration).
The ORs for each of the 12 cohorts are shown in a Forest plot for those with the duration of
diabetes of 2–8 years (Fig. 1) and nine or more years (Fig. 2). Four cohorts (HPFS, PHS,
WHS, and NYU) were not included in the summary estimates and are not displayed because
these cohorts contained too few cases with diabetes that matched these criteria to calculate
meaningful estimates. For diabetes duration of 2–8 years, the ORs are consistent across the
cohorts indicating a positive association of diabetes with pancreatic cancer, with a range of
ORs from 1.06 to 12.0 with the exception of NHS (OR = 0.43, 95 % CI: 0.04, 5.07). The
risks seen in Fig. 1 are attenuated for each cohort in Fig. 2, with risk estimates for most
studies being approximately null. The wide confidence limits seen were a consequence of
low case numbers in many cohorts.
Discussion
The purpose of the current study was to examine the association between diabetes and
pancreatic adenocarcinoma risk by pooling data from nested case–control studies included in
the NCI Pancreatic Cancer Cohort Consortium (PanScan). Diabetes appears to be a
moderate risk factor for pancreatic cancer risk with 40 % higher risk seen in diabetics than
non-diabetics. Those with a duration of diabetes of 2–8 years were at the highest risk, being
1.8 times as likely to develop pancreatic cancer as non-diabetics. No increased risk was
observed for those with the longest duration of diabetes (>9 years). The association between
diabetes and pancreatic adenocarcinoma was not modified by gender, smoking, age, or BMI.
Diabetes was established as a possible risk factor for pancreatic cancer based primarily on
two well-conducted meta-analyses [14, 15] that produced summary estimates that are very
similar to ours. The first meta-analysis of nine cohort studies and 11 case–control studies
reported a pooled relative risk (RR) of 2.1 and found higher risk in the cohort studies (RR:
2.6) than the case–control studies (RR: 1.8) [14]. A subsequent meta-analysis of 19 cohort
studies and 17 case–control studies also found slightly lower risk for cohort studies (RR:
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1.73) than the case–control studies (RR: 1.94), with an overall summary OR of 1.82[15].
Both meta-analyses excluded cases diagnosed with diabetes within 1 year of pancreatic
cancer, which could produce slightly higher risk estimates than those provided here
excluding those with a duration of diabetes <2 years. However, our risk estimates were quite
similar (1.79 vs. 2.1 and 1.71). Since the publication of these meta-analyses, additional
epidemiologic studies have been conducted. The vast majority have reported similar positive
associations [28–31], with ORs ranging from 1.8 to 3.2. One population-based cohort of
approximately 18,000 men observed a nonsignificant association, of diabetes with
pancreatic cancer mortality (RR: 2.47, 95 % CI: 0.79, 7.75), but was limited by low numbers
of cases [32]. Another study of national hospital and cancer registries for type 2 diabetics
hospitalized in Sweden with up to 40 years of follow-up observed elevated standardized
incidence ratios (SIR), which were standardized to the general Swedish population, for
pancreatic cancer risk, with SIRs of 6.08 overall, 3.57 excluding the first year of follow-up,
and 1.80 excluding the first 5 years of follow-up [33]. Nonetheless, interpretation of the
association between diabetes and pancreatic cancer has been complicated by the difficulty of
developing large prospective studies with sufficient numbers of cases and follow-up periods.
Many of these studies have included small numbers of cases with limited follow-up
information.
In contrast to our results, an increased risk of pancreatic cancer for those with the greatest
duration of diabetes was observed in the two meta-analyses discussed above. For example,
Huxley et al. [15] reported a slight attenuation of risk with duration > 5 years, compared to
1–4 years, yet saw elevated risk with diabetes regardless of duration (RR: 2.05 for duration
1–4 years, RR: 1.54 for duration 5–9 years and RR: 1.51 duration for duration > 10 years).
One might expect a longer exposure to diabetes to be associated with higher cancer risk;
however, type 2 diabetes begins with insulin resistance and relative hyperinsulinemia. Later
in the natural history, there is further loss of the islet β-cells, resulting in hypoinsulinemia
[34]. If insulin levels contribute to diabetes and act as an independent risk factor for
pancreatic cancer, then it follows that patients with a longer duration of diabetes, who are
more likely to be hypoinsulinemic, would be at lower risk compared to those who are earlier
in their diabetes natural history and have higher serum insulin levels. In fact, biomarker
studies have demonstrated greater risk of pancreatic cancer with prediagnostic elevations in
post-load plasma glucose [35, 36], C-peptide in nonfasting blood specimens [37], serum and
plasma glucose [38, 39], HbA1c [40], and insulin [41]. Furthermore, the diabetes drug
metformin, an insulin sensitizer which tends to lower insulin levels, has been associated with
decreased pancreatic risk, whereas insulin and insulin secretagogues have been associated
with increased pancreatic cancer risk, [42, 43] offering additional support to the hypothesis
that insulin is the agent affecting risk. However, it should be recognized that many diabetics
receive insulin injections, and it is possible that the insulin levels resulting from the
administered insulin would also contribute to risk of pancreatic cancer. Studies of type 1
diabetics who receive routine insulin treatment have not demonstrated an excess risk of
pancreatic cancer, albeit these studies are limited by very low numbers [42, 43]. It is
possible that many of the type 1 diabetics were relatively hypoinsulinemic even after the
insulin injections, since type 1 diabetes patients are generally less insulin-resistant and
relatively hypoinsulinemic compared to type 2 diabetes patients. The lack of an effect of
administered insulin may also be the result of differences in the sites of action due to
differences in the site of production as compared with routes of administration.
Alternatively, there may be additional biological abnormalities beyond insulin and the IGF
pathway involved in diabetes (e.g., C-peptide or elevated circulating free fatty acids) that
influence pancreatic cancer risk.
The relationship between diabetes and pancreatic cancer risk is further complicated by the
potential for pancreatic cancer to cause diabetes [34]. Thus, it is vital in studies of risk to
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exclude any patient in whom diabetes has been caused by pancreatic cancer. Although there
are no clinical features to distinguish diabetes due to pancreatic cancer from other diabetes, a
short duration between diabetes diagnosis and pancreatic cancer diagnosis suggests that
diabetes may result from pancreatic cancer [13, 44]. A recent case–control study of
pancreatic cancer cases (n = 736) and age- and sex-matched controls (n = 1,875) evaluated
the temporality of the relationship using clinical information of fasting glucose levels
collected up to 5 years before diagnosis of pancreatic cancer [13]. The proportion of cases
with diabetes and controls with diabetes was similar in the time period 3–5 years before
pancreatic cancer diagnosis, with a small increase in the proportion of diabetic cases
reported 3 years before diagnosis, and a large increase in the proportion of diabetic cases
within 2 years of a pancreatic cancer diagnosis. These results suggest that diabetes
discovered during the 2 years prior to pancreatic cancer diagnosis is likely the result of the
cancer. In an effort to minimize the effect of possible reverse causality on our results, we
excluded individuals diagnosed with diabetes within 2 years of their pancreatic cancer
diagnosis. This type of reverse causality is less of a concern among those with a longer
duration because pancreatic cancer is a highly fatal disease and it is unlikely that someone
with undetected pancreatic cancer would remain healthy for a period of many years. A
recent study on the natural history of pancreatic cancer found that almost 20 years span from
the initiating mutation until cancer death; with 11.7 years from mutation to the rise of a
parental clone, another 6.8 years until the development of metastatic subclones, and 2.7
years until death, on average [45]. Interpreting our findings that diabetes is a risk factor for
those with diabetes for 2–8 years, but not longer than 9 years, before pancreatic cancer
diagnosis, in light of this analysis suggests that the effect of diabetes occurs during the phase
where the parental clone leads to the development of metastatic subclones and their escape
from the pancreas.
Obesity is the leading cause of type 2 diabetes. Both obesity and diabetes appear to be risk
factors of pancreatic cancer but it is difficult to fully tease apart their independent effects.
Many of the hypothesized biologic pathways are the same for diabetes and obesity including
insulin resistance, inflammation, and oxidative stress [12, 35]. Although the results have
been mixed, most studies have found that higher BMI is correlated with an increased risk of
pancreatic cancer [12, 46], as well as younger age at onset and poorer survival [47]. A recent
study of the same pooled data used here found elevated risk for those in the highest quartile
of BMI (OR = 1.33, 95 % CI:1.12, 1.58) [9], as did a similar study of 14 cohorts with
>2,000 pancreatic cancer cases which found the obese to be at 54 % higher risk [48]. Our
associations with diabetes remained after adjustment for BMI, as did the BMI associations
when adjusted for diabetes, suggesting that they may have separate effects on risk.
This study had a number of strengths including a large number of cases with considerable
follow-up. The prospective nature of the cohorts allowed diabetes status to be assessed
before the diagnosis of cancer, eliminating recall bias. By excluding patients diagnosed with
diabetes within 2 years of a pancreatic cancer diagnosis, we minimized the possibility that
associations seen here are due to reverse causality. The major limitation is that we measured
diabetes from self-report in cohorts of people who were enrolled before the recent rise in
diabetes. Recent estimates of the prevalence of diabetes in the United States among those
over 20 years of age are approximately 11 % [49]. Most of the cohorts included in this
analysis had much lower prevalence, with the exception of CLUE II, in large part because
they occurred decades earlier. Further, approximately one-third of diabetics are estimated to
be undiagnosed [50]. The resulting misclassification would be expected to be non-
differential across cases and controls and would tend to bias our results toward the null. In
addition, self-reported estimations of duration may not be accurate and we were unable to
include glucose or insulin measures in the models. There is also the possibility of
misclassification of pancreatic cancer cases; however, cases were rigorously confirmed and
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it is unlikely that subjects would remain healthy with asymptomatic pancreatic cancer for
years. Due to very low numbers of people reporting type 1 diabetes in our sample (n = 4
among cases), we did not analyze type 1 and type 2 diabetes separately and thus cannot
assess whether the association with pancreatic cancer is different. We did not have available
medication data and therefore were unable to measure the effect of diabetes-related
treatments, which have been shown to affect pancreatic cancer risk [31]. It is possible that
this may account for some of the attenuation in risk seen by duration, as those with the
longest duration of diabetes would likely have received the treatments associated with
decreased risk for the longest period of time.
In summary, our results support a growing literature that suggests diabetes is an independent
risk factor for pancreatic cancer. With the rise of the obesity epidemic, the number of
diabetics in the United States and globally is increasing rapidly. There are few identified risk
factors for pancreatic cancer and even fewer that can be modified. Reducing diabetes by
controlling obesity could benefit pancreatic cancer rates, in addition to the many other
known health benefits.
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Risk estimates for pancreatic cancer associated with diabetes by study for 2–8 years
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Risk estimates for pancreatic cancer associated with diabetes by study for 9+ years
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Table 2
Selected baseline characteristics of those included in the pancreatic cancer cohort consortium
Cases Controls
Number % Number %
Age at baseline (years)
  ≤ 50 41 2.9 25 1.5
  51–60 213 12.9 184 10.6
  61–70 652 39.5 708 40.9
  71–80 613 37.2 692 40.0
   81+ 131 7.9 121 7.0
Gender
  Male 783 47.5 816 47.2
  Female 867 52.6 914 52.8
Ancestral race
  European 1,465 88.8 1,574 91.0
  African 32 1.9 33 1.9
  Asian 102 6.2 105 6.1
  Other/Unknown 51 3.1 18 1.0
Smoking status
  Non-smoker 638 38.7 730 42.2
  Former smoker 551 33.4 611 35.3
  Current smoker 455 27.6 381 22.0
  Unknown 6 0.4 8 0.5
Body mass index (kg/m2) at baseline
  < 18.5 15 0.9 20 1.2
  18.5– < 2 623 37.8 726 42.0
  25− < 30 676 41.0 657 38.0
   30+ 329 19.9 322 18.6
  Missing 7 0.4 5 0.3
Personal history of diabetes
  Yes 170 10.3 123 7.1
  No 1,480 89.7 1,607 92.9
Personal history of pancreatitis
  Yes 21 1.3 2 0.1
  No 550 33.3 565 32.7
  Missing 1,079 65.4 1,163 67.2
Family history of pancreatic cancer
  Yes 44 2.7 25 1.5
  No 729 44.8 760 43.9
  Missing 877 53.2 945 54.6
Table includes all participants with diabetes information, including those diagnosed with diabetes less than 2 years before pancreatic cancer
diagnosis or selection as a control (n = 36) and also any participants diagnosed with diabetes after cancer/selection (n = 4)
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Table 4
Pancreatic cancer risk by duration of diabetes
Population Case Control Total ORa (95 % CI)
All participants
  Never 1,480 1,607 3,087 Ref
  <2 Years 29 11 40 3.02 (1.47, 6.21)
  2–3 Years 11 11 22 1.10 (0.46, 2.62)
  3–4 Years 27 10 37 2.97 (1.41, 6.26)
  5 Years 15 11 26 1.42 (0.64, 3.16)
  6 Years 17 11 28 1.66 (0.76, 3.63)
  7–8 Years 21 13 34 1.95 (0.96, 3.96)
  9–11 Years 23 17 40 1.44 (0.76, 2.74)
12–15 Years 11 17 28 0.74 (0.34, 1.61)
  16+ Years 16 22 38 0.89 (0.46, 1.74)
a
Adjusted by age, race, gender, study, smoking, alcohol use, body mass index, and family history of pancreatic cancer
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